Skip to main content

Table 2 28-day uncorrected and PCR-corrected efficacy estimate, by drug, by site, Madagascar, 2018

From: Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018

  Ankazomborona Matanga
ASAQ
n = 83
AL
n = 85
ASAQ
n = 84
AL
n = 83
Parasitemia day 2, n (%) 1 (1) 14 (16) 8 (10) 9 (10)
Parasitemia day 3, n (%) 0 0 1 (1) 1 (1)
Early treatment failure, n (%) 0 0 1 0
Late clinical failure, n (%) 0 1 (1) 1 (1) 2 (2)
Late parasitological failure, n (%) 0 0 3 (4) 12 (14)c
Recrudescencea 0 0 2 2
Day 14–21 0 0 1 0
Day 22–28 0 0 1 2
Reinfection 0 1 2 11
Day 14–21 0 0 0 3
Day 22–28 0 1 2 8
Per protocol efficacy, n (% [95% CI]), uncorrected 83 (100 [96–100]) 84 (99 [94–100) 79 (94 [87–98]) 69 (83 [73–90])
Per protocol efficacy, n (% [95% CI]), PCR-correctedb 83 (100 [96–100]) 84 (100 [96–100]) 79 (97 [90–100]) 69 (95 [87–99])
Kaplan–Meier estimate of efficacy, uncorrected (% [95% CI]) 100 (100–100) 99 (97–100) 95 (91–100) 83 (76–92)
Kaplan–Meier estimate of efficacy, PCR-corrected (% [95% CI])a 100 (100–100) 100 (99–100) 98 (95–100) 95 (91–100)
  1. ASAQ artesunate-amodiaquine, AL artemether-lumefantrine, CI confidence interval
  2. aPosterior probability of recrudescence ≥ 0.5
  3. bPosterior probability of recrudescence rather than whole numbers used for PCR-corrected estimates
  4. cOne late treatment failure had an indeterminate PCR